Faruqi & Faruqi Reminds Investors of Legal Action Against Picard Medical with Deadline Approaching

Urgent Reminder for Investors of Picard Medical

Faruqi & Faruqi, LLP, an esteemed national securities law firm, is currently investigating potential claims against Picard Medical, Inc. (NYSE: PMI). All investors who purchased or acquired shares in Picard Medical between September 2, 2025, and October 31, 2025, are urged to act promptly as the deadline to seek lead plaintiff status in a federal securities class action lawsuit is looming—April 3, 2026.

Background of the Investigation

Within a short span, Picard Medical's share price experienced a stark decline, illustrating the volatility often associated with this young company. On October 24, 2025, shares plummeted to $5.31, marking a dramatic drop from $13.20 just one day prior, equivalent to a staggering 59.8% decrease in value. Such drastic declines may hint at underlying malfeasance that Faruqi & Faruqi aims to uncover.

Allegations Against Picard Medical

The lawsuit highlights several key allegations against Picard Medical and its executive team:
1. Fraudulent Stock Promotion Schemes: The complaint alleges that inappropriate manipulation of stock prices occurred through misleading social media campaigns led by impersonated financial professionals.
2. Insider Trading: It is claimed that insiders or affiliates exploited offshore accounts to orchestrate a coordinated share dump during the price-fueled hype, presenting a serious breach of trust and legal conduct.
3. Omission of Key Disclosures: The company purportedly failed to disclose risks associated with the misinformation campaign that was affecting the stock price, directly impacting shareholders.

What Investors Should Know

Faruqi & Faruqi underscores the importance of joining the class action for those who suffered financial losses during this time frame. Investors can also choose to remain absent from the lawsuit, yet the decision to take an active role will not affect their eligibility for any potential recovery claims.

How to Get Involved

Investors interested in discussing their legal options regarding this case are prompted to reach out to Josh Wilson, a Senior Partner at Faruqi & Faruqi, directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Furthermore, the firm is actively inviting information from whistleblowers, former employees, and other stakeholders who may have insights into Picard Medical's operations.

For more detailed information about the circumstances surrounding Picard Medical, stakeholders can visit Faruqi & Faruqi’s official website.

Staying Updated

As developments unfold, keep abreast of updates via LinkedIn, X (formerly Twitter), or Facebook, ensuring that you're informed about this significant legal matter. Faruqi & Faruqi promises confidentiality in all communications, catering to the sensitive nature of these discussions.

Conclusion

With an impending deadline, investors affected by Picard Medical’s drastic share price changes should not delay in pursuing their rights. The actions taken now might determine the extent of recovery and accountability for the alleged missteps made by the company’s executives. It is crucial to advocate for transparency and justice in the ever-evolving landscape of securities law.